Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Eidos Therapeutics Inc (EIDX)

Eidos Therapeutics Inc (EIDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer Globe NewsWire - Mon Jun 28, 2021

REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of...

BMEA : 10.83 (-2.96%)
EIDX : 122.21 (-4.85%)
BBIO : 24.78 (-0.68%)
IOVA : 11.33 (-3.33%)
BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update Globe NewsWire - Thu Feb 25, 2021

– Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory...

BBIO : 24.78 (-0.68%)
EIDX : 122.21 (-4.85%)
BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc. Globe NewsWire - Tue Jan 26, 2021

PALO ALTO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of...

BBIO : 24.78 (-0.68%)
EIDX : 122.21 (-4.85%)
Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc. Globe NewsWire - Tue Jan 19, 2021

PALO ALTO, Calif. and SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) today announced...

BBIO : 24.78 (-0.68%)
EIDX : 122.21 (-4.85%)
BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Announce January 21, 2021 Election Deadline for Merger Globe NewsWire - Wed Jan 13, 2021

PALO ALTO, Calif. and SAN FRANCISCO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) announced today...

BBIO : 24.78 (-0.68%)
EIDX : 122.21 (-4.85%)
EIDOS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of EIDX and Encourages Investors to Contact the Firm Globe NewsWire - Mon Jan 4, 2021

NEW YORK, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Eidos Therapeutics,...

EIDX : 122.21 (-4.85%)
BBIO : 24.78 (-0.68%)
Leading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma and Eidos Therapeutics Stockholders Vote “FOR” Proposed Merger Globe NewsWire - Mon Jan 4, 2021

PALO ALTO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced that leading proxy advisory firm Institutional Shareholder Services (“ISS”) recommends that...

BBIO : 24.78 (-0.68%)
EIDX : 122.21 (-4.85%)
Lifshitz Law Firm, P.C. Announces Investigation of EIDX, NAV, STND, and WTRE AccessWire - Sun Jan 3, 2021

NEW YORK, NY / ACCESSWIRE / January 3, 2021 / Lifshitz Law Firm, P.C.: Eidos Therapeutics, Inc. (NASDAQ:EIDX) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in...

EIDX : 122.21 (-4.85%)
NAV : 44.50 (+0.16%)
STND : 33.00 (+0.06%)
WTRE : 16.46 (-0.41%)
MERGER INVESTIGATION ALERT: Halper Sadeh LLP Encourages CKH, PS, WDR, and EIDX Shareholders to Contact the Firm AccessWire - Sat Jan 2, 2021

NEW YORK, NY / ACCESSWIRE / January 2, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: SEACOR Holdings Inc. (NYSE:CKH) concerning potential...

EIDX : 122.21 (-4.85%)
PS : 22.45 (+0.13%)
CKH : 41.50 (+0.22%)
WDR : 24.98 (-0.04%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers – CKH, WDR, NAV, EIDX Globe NewsWire - Wed Dec 30, 2020

NEW YORK, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

CKH : 41.50 (+0.22%)
WDR : 24.98 (-0.04%)
NAV : 44.50 (+0.16%)
EIDX : 122.21 (-4.85%)

Barchart Exclusives

Why is Gold Ignoring Higher Rates and a Stronger Dollar? Barchart - 6 minutes ago
Gold is the world’s oldest currency. Historically, rising interest rates and a strong U.S. dollar have been bearish for gold prices. Meanwhile, the traditional trading patterns have not impacted gold over the past weeks as rates have increased, the dollar index rallied, and gold has continued to make higher lows and higher highs in record territory. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot